Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897492 | 0.86 | KCNH2 (0.31) | KCNH2ALDH1A1POLBKMT2AAGTR1 | |
| SCHEMBL5896841 | 0.84 | BRD4 (0.32) | KMT2A | |
| SCHEMBL5896460 | 0.82 | BRD4 (0.31) | — | |
| SCHEMBL5896693 | 0.79 | NPY5R (0.34) | ALDH1A1KMT2A | |
| SCHEMBL5896560 | 0.78 | FLT1 (0.34) | — | |
| SCHEMBL5896427 | 0.78 | BRD4 (0.31) | — | |
| SCHEMBL5896348 | 0.78 | KCNH2 (0.37) | KCNH2ALDH1A1KMT2A | |
| SCHEMBL3070588 | 0.77 | TP53 (0.38) | ALDH1A1POLBKMT2A | |
| SCHEMBL3061489 | 0.77 | S1PR1 (0.34) | ALDH1A1KMT2A | |
| SCHEMBL3061416 | 0.76 | RPS6KA5 (0.43) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030144-B2 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1499608-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003093263-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | GABRA1, GABRA3, GABRA2 | KCNH2 1017/4885ALDH1A1 719/4885POLB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.